Cara Therapeutics to Present at the Jefferies Healthcare Conference

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) has announced Derek Chalmers, CEO, will engage in a fireside chat during the Jefferies Healthcare Conference on June 1, 2021, at 11:00 a.m. ET. Interested parties can watch the live webcast on the company's website, with an archived version available for 30 days post-event. Cara Therapeutics focuses on developing solutions to alleviate pruritus using KORSUVA (CR845/difelikefalin), which has made significant progress in clinical trials and has received FDA Priority Review for moderate-to-severe pruritus treatment.

STAMFORD, Conn., May 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Tuesday, June 1, 2021 at 11:00 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system and on immune cells. In the Company’s KALM™-1 and KALM-2 Phase 3 trials and two Phase 2 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe CKD-aP. The FDA has accepted and granted Priority Review for the NDA for KORSUVA (difelikefalin) Injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in PBC and NP patients with moderate-to-severe pruritus.

The FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

MEDIA CONTACT:
Claire LaCagnina
6 Degrees
315-765-1462
clacagnina@6degreespr.com

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com

FAQ

When will the Cara Therapeutics fireside chat take place?

The Cara Therapeutics fireside chat is scheduled for June 1, 2021, at 11:00 a.m. ET.

Where can I watch the Cara Therapeutics presentation?

The presentation can be accessed via a live webcast on the Cara Therapeutics website under the 'Events & Presentations' section.

What is KORSUVA and its significance for Cara Therapeutics?

KORSUVA (CR845/difelikefalin) is a first-in-class KOR agonist developed by Cara Therapeutics, targeting pruritus in patients with moderate-to-severe conditions.

What is the PDUFA target action date for KORSUVA?

The PDUFA target action date for KORSUVA is August 23, 2021.

What progress has KORSUVA shown in clinical trials?

KORSUVA has demonstrated significant reductions in itch intensity and improvement in quality of life for hemodialysis patients with moderate-to-severe pruritus.